Navigation Links
PAREXEL International to Present at Oppenheimer 19th Annual Healthcare Conference
Date:10/31/2008

BOSTON, Oct. 31 /PRNewswire-FirstCall/ -- PAREXEL International Corporation (Nasdaq: PRXL) announced today it will be presenting at the Oppenheimer 19th Annual Healthcare Conference in New York, NY. James Winschel, Senior Vice President and Chief Financial Officer will be making a formal presentation on PAREXEL at 1:20 p.m. EST on Monday, November 3, 2008.

The presentation will be available under the "Upcoming Events" section on PAREXEL's "Investors" homepage at http://www.PAREXEL.com. After the conference, a PDF version of this presentation will be available under the "Webcasts and Presentations" section on our "Investors" homepage.

About the Company

PAREXEL International Corporation is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, medical communications and consulting services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has over 9,180 employees. For more information about PAREXEL International visit http://www.parexel.com

PAREXEL is a registered trademark of PAREXEL International Corporation, and Perceptive Informatics is a trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of their respective business and are hereby acknowledged.

CONTACT: Jill Baker, Vice President of Investor Relations

+1-781-434-4118


'/>"/>
SOURCE PAREXEL International Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. PAREXEL Partners with Glenmark to Win the Good Clinical Practice Journal Award for Most Innovative Patient Recruitment Strategy
2. PAREXEL Corporate Vice President Dr. Alberto Grignolo Receives Lifetime Achievement Award From Good Clinical Practice Journal
3. PAREXEL Consulting Quantifies Speed to Market: First-Cycle Approval for NME Produces $640 Million in Incremental Revenue on Average
4. PAREXEL International to Present at William Blair Small-Cap Growth Stock Conference
5. PAREXEL International Updates Financial Guidance in Conjunction With the Acquisition of ClinPhone Plc and Other Factors
6. PAREXEL International To Present at Thomas Weisel Partners Healthcare Conference
7. PAREXEL Data Indicate U.S. Marketing Applications for New Molecular Entities Bounce Back
8. PAREXEL Closes the Acquisition of ClinPhone
9. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
10. PAREXEL Promotes Dr. Mark A. Goldberg to Chief Operating Officer
11. PAREXEL Announces Date of Fourth Quarter and Fiscal Year 2008 Earnings Release and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... , June 27, 2016  Global demand ... 4.6 percent through 2020 to $7.2 billion.  This ... and beverages, cleaning products, biofuel production, animal feed, ... biotechnology, diagnostics, and biocatalysts). Food and beverages will ... driven by increasing consumption of products containing enzymes ...
(Date:6/27/2016)... ... 2016 , ... Newly created 4Sight Medical Solutions ... healthcare market. The company's primary focus is on new product introductions, to include ... are necessary to help companies efficiently bring their products to market. , The ...
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... Mass. , June 23, 2016   ... development of novel compounds designed to target cancer ... napabucasin, has been granted Orphan Drug Designation from ... the treatment of gastric cancer, including gastroesophageal junction ... stemness inhibitor designed to inhibit cancer stemness pathways ...
Breaking Biology Technology:
(Date:5/24/2016)... facilitates superior patient care by providing unparalleled technology to leaders of the medical imaging ... product recently added to the range of products distributed by Ampronix. Photo ... ... ... News ...
(Date:5/16/2016)... 16, 2016   EyeLock LLC , a market ... opening of an IoT Center of Excellence in ... the development of embedded iris biometric applications. ... convenience and security with unmatched biometric accuracy, making it ... from DNA. EyeLock,s platform uses video technology to deliver ...
(Date:5/9/2016)... , UAE, May 9, 2016 ... it comes to expanding freedom for high net worth ... Even in today,s globally connected world, there is still ... system could ever duplicate sealing your deal with a ... second passports by taking advantage of citizenship via investment ...
Breaking Biology News(10 mins):